Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of GX-G3 versus Neulasta as adjunct to R-CHOP in non-Hodgkin lymphoma
2015-002693-20Phase 2Completed
- Sponsor
- Ilkogen
- Start
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of GX-G3 and pegfilgrastim in chemotherapy-induced neutropenia (CIN) (4 arms), sponsored by Ilkogen. Primary endpoint: Time to recovery from severe neutropenia in cycles 1 and 2. Started Nov 2015; status: completed.
02
Drugs
GX-G3pegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on 2015-002693-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002693-20.